Prosecution Insights
Last updated: October 02, 2026

Examiner: LUNDE, GRACE HENRY

Tech Center 1600 • Art Units: 1641 1643

This examiner grants 63% of resolved cases

Analysis

Grace Henry Lunde is an examiner in Tech Center 1600 and Art Unit 1641. The examiner has 27 resolved cases. The allowance rate pct is 63.0, and the interview lift pct is 38.9. The median days to allowance is 1338. This 1338-day figure is the median time for an application to reach allowance. The 63.0 percent allowance rate indicates the frequency of successful outcomes. The 38.9 percent interview lift pct suggests that interviews are an effective tool for practitioners.

With 27 resolved cases, the 63.0 percent allowance rate is an informative metric. The 38.9 percent interview lift pct provides a strategic option for applicants in Art Unit 1641. The 1338 days to allowance reflects the timeline for prosecution in Tech Center 1600. The 63.0 percent allowance rate is a key factor for evaluating the likelihood of a grant. The 27 resolved cases provide an initial basis for these statistics. The 1338 days to allowance is a specific benchmark for pendency.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

63.0%
Allow Rate
+3.0% vs TC avg
58
Total Applications
+38.9%
Interview Lift
1338
Avg Prosecution Days
Based on 27 resolved cases, 2023–2026

Rejection Statute Breakdown

2.9%
§101 Eligibility
14.6%
§102 Novelty
26.0%
§103 Obviousness
31.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17908545 Membrane Ubiquitin ligases to target protein degradation Non-Final OA UMC Utrecht Holding B.V.
17635119 ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS Non-Final OA H. Lee Moffitt Cancer Center and Research Institute, Inc.
17870876 MULTISPECIFIC ANTIBODIES FOR USE IN TREATING DISEASES Final Rejection Yeda Research and Development Co. Ltd.
18023536 NOVEL CELL LINES, METHODS OF PRODUCING NATURAL KILLER CELLS AND USES THEREOF Non-Final OA City of Hope
17630467 ANTI-CTLA4-ANTI-PD-1 BISPECIFIC ANTIBODY AND USES THEREOF Non-Final OA Akeso Pharmaceuticals, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month